Atreca Announces First Patient Dosed in Phase 1b Clinical Trial of ATRC-101 in Patients with Select Solid Tumors
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that the first patient has been dosed in a Phase 1b first-in-human clinical trial evaluating ATRC-101 in patients with select solid tumor cancers. ATRC-101, a monoclonal antibody derived from a human antibody identified in a cancer patient via Atreca’s drug discovery platform, targets a ribonucleoprotein (RNP) complex and is believed to function through Driver Antigen Engagement, a novel mechanism of action in oncology.
“Dosing of the first patient in our Phase 1b study of ATRC-101 is an important milestone marking our transition to a clinical-stage company,” said John Orwin, Chief Executive Officer. “ATRC-101 has demonstrated potent single-agent anti-tumor activity in multiple preclinical solid tumor models and we believe, through both its novel target and mechanism of action, that this antibody represents an exciting potential new approach in oncology. We look forward to reporting initial data from this study in the second half of 2020.”
The Phase 1b open-label, dose escalation, monotherapy trial with an adaptive 3+3 design will enroll patients with colorectal, ovarian, non-small cell lung and breast cancers and acral melanoma. Over 50% of tumor tissue samples evaluated by Atreca in each of these cancer types were positive for the antigenic target of ATRC-101, an RNP complex. Major objectives of the trial are to characterize the safety of ATRC-101 and determine a recommended dose for future studies. The trial will also evaluate potential biomarkers and initial signals of clinical activity of ATRC-101. Upon confirmation of safety, Atreca plans to test ATRC-101 further as a single agent and in combination with checkpoint inhibitors and select chemotherapeutics.
For more information about the clinical trial design please visit www.clinicaltrials.gov (NCT04244552).
About Atreca, Inc.
Source: Atreca, Inc.
Get Your Factories Connected -- Fast!
IoT Evolution #TECHSUPERSHOW Expo Hall Open